On January 7, 2022 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, reported that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022 (Press release, CNS Pharmaceuticals, JAN 7, 2022, https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-hc-wainwright-bioconnect-conference-301456183.html [SID1234598430]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, January 10, 2022, at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (www.cnspharma.com). The webcast replay will be archived for 90 days following the event.